Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Genfit SA ( (GNFT) ) is now available.
On September 19, 2025, GENFIT announced the discontinuation of its VS-01 program for Acute-on-Chronic Liver Failure (ACLF) due to safety concerns, specifically a serious adverse event in the UNVEIL-IT® clinical trial. The company will refocus VS-01 development on Urea Cycle Disorder (UCD), a condition with significant unmet medical needs. This strategic shift is expected to reduce operating expenses and extend GENFIT’s cash runway beyond 2028, while allowing the company to explore new approaches in ACLF care. GENFIT remains committed to its other ACLF programs and aims to deliver positive results from its pipeline, including safety data for G1090N by year-end.
The most recent analyst rating on (GNFT) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Genfit SA stock, see the GNFT Stock Forecast page.
Spark’s Take on GNFT Stock
According to Spark, TipRanks’ AI Analyst, GNFT is a Neutral.
Genfit SA’s overall stock score reflects a strong financial recovery with significant revenue growth and improved cash flow. The technical indicators are positive, supporting a favorable short-term outlook. However, the high P/E ratio suggests potential overvaluation, which is a significant risk factor. The absence of earnings call insights and corporate events limits additional context.
To see Spark’s full report on GNFT stock, click here.
More about Genfit SA
GENFIT S.A. is a biopharmaceutical company focused on developing therapies for rare and life-threatening liver diseases, including Acute-on-Chronic Liver Failure (ACLF), Urea Cycle Disorder (UCD), and cholangiocarcinoma (CCA). The company has a strong history in liver disease research and offers a diversified R&D portfolio with several programs at various stages of development. GENFIT is headquartered in Lille, France, and is listed on the Nasdaq Global Select Market and Euronext Paris.
Average Trading Volume: 3,459
Technical Sentiment Signal: Buy
Current Market Cap: $210.7M
Find detailed analytics on GNFT stock on TipRanks’ Stock Analysis page.